Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

Nuvalent (NASDAQ:NUVL) is one of the best up and coming stocks with highest upside potential. On April 7, Nuvalent submitted ...

Is Zykadia Right for Me? Your health care provider will consider what type of lung cancer you have and whether it has spread to help choose the right treatment for you. Zykadia is used for NSCLC that ...

Lung cancer is the number one cause of cancer-related death around the world,i and an estimated 234,580 new cases of lung cancer are expected to be diagnosed in the U.S. in 2024.ii NSCLC accounts for ...

In 5-year follow-up data from the phase III CROWN trial of ALK-positive advanced non-small cell lung cancer (NSCLC), patients receiving lorlatinib (Lorbrena) had the longest progression-free survival ...

Ensartinib offers improved progression-free survival for ALK-positive NSCLC compared with crizotinib, with a median PFS of 25.8 months vs 12.7 months. Adverse events with ensartinib are mostly mild, ...

Many lung cancer patients who have never smoked and don't work around toxic chemicals or carcinogens have been found instead to have a defective gene that drives their cancer. Now, an FDA- approved ...

(CAMBRIDGE, MASS.) December 05, 2024 – Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer ...

Quantifying clinical harm and financial waste from failure to deploy personalized medicine for patients with metastatic non-small cell lung cancer in the United States. This is an ASCO Meeting ...

Previously demonstrated survival benefits of crizotinib (Xalkori, Pfizer Inc.) as an adjuvant treatment for advanced ALK-positive non-small cell lung cancer (ALK+NSCLC) did not extend to the setting ...